Nicole M A Le Saux1,2, Jennifer Bowes2, Isabelle Viel-Thériault1,3, Nisha Thampi1,2, Julie Blackburn1,4, Melanie Buba1, Mary-Ann Harrison2, Nick Barrowman2. 1. Division of Infectious Diseases, Children's Hospital of Eastern Ontario, Ottawa, Ontario. 2. Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario. 3. Service d'Infectiologie, Département de Pédiatrie, Centre hospitalier université Laval et Centre mère-enfant Soleil, Québec, Québec. 4. Services de microbiologie et de maladies infectieuses, CHU Sainte-Justine, Montréal, Québec.
Abstract
BACKGROUND: Aminopenicillins are recommended empiric therapy for community-acquired pneumonia (CAP). The aim of the study was to assess treatment over a 5-year period after CAP guideline publication and introduction of an antimicrobial stewardship program (ASP). METHODS: Using ICD-10 discharge codes for pneumonia, children less than 18 years admitted to the Children's Hospital of Eastern Ontario January 1, 2012 and December 31, 2016 were identified. Children ≥ 2 months with consolidation were included. One day of therapy (DOT) was one or more doses of an antimicrobial given for 1 day. RESULTS: Of 1,707 patients identified, 713 met inclusion criteria. Eighteen (2.5%) had bacteria identified by culture and 79 of 265 (29.8%) had Mycoplasma pneumoniae detected. Mean DOT/1,000 patient days of aminopenicillins/penicillin (AAP) increased by 18.1% per year (95% confidence interval [CI] -0.2, 39.9%) and decreased by 37.6% per year (95% CI -56.1, -11.3%) for second- and third-generation cephalosporins in the post-ASP period. The duration of discharge antimicrobials decreased. Of 74 (10.4%) patients who had pleural fluid drained, 35 (47.3%) received more than 5 days of AAP and ≤ 5 days of second-/third-generation cephalosporins with no difference in median length of stay nor mean duration of antimicrobials. CONCLUSIONS: Implementation of CAP management guidelines followed by prospective audit and feedback stewardship was associated with a sustained decrease in the use of broad-spectrum antibiotics in childhood CAP. Use of AAP should also be strongly considered in patients with effusions (even if no pathogen is identified), as clinical outcome appears similar to patients treated with broad-spectrum antimicrobials.
BACKGROUND: Aminopenicillins are recommended empiric therapy for community-acquired pneumonia (CAP). The aim of the study was to assess treatment over a 5-year period after CAP guideline publication and introduction of an antimicrobial stewardship program (ASP). METHODS: Using ICD-10 discharge codes for pneumonia, children less than 18 years admitted to the Children's Hospital of Eastern Ontario January 1, 2012 and December 31, 2016 were identified. Children ≥ 2 months with consolidation were included. One day of therapy (DOT) was one or more doses of an antimicrobial given for 1 day. RESULTS: Of 1,707 patients identified, 713 met inclusion criteria. Eighteen (2.5%) had bacteria identified by culture and 79 of 265 (29.8%) had Mycoplasma pneumoniae detected. Mean DOT/1,000 patient days of aminopenicillins/penicillin (AAP) increased by 18.1% per year (95% confidence interval [CI] -0.2, 39.9%) and decreased by 37.6% per year (95% CI -56.1, -11.3%) for second- and third-generation cephalosporins in the post-ASP period. The duration of discharge antimicrobials decreased. Of 74 (10.4%) patients who had pleural fluid drained, 35 (47.3%) received more than 5 days of AAP and ≤ 5 days of second-/third-generation cephalosporins with no difference in median length of stay nor mean duration of antimicrobials. CONCLUSIONS: Implementation of CAP management guidelines followed by prospective audit and feedback stewardship was associated with a sustained decrease in the use of broad-spectrum antibiotics in childhood CAP. Use of AAP should also be strongly considered in patients with effusions (even if no pathogen is identified), as clinical outcome appears similar to patients treated with broad-spectrum antimicrobials.
Authors: John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson Journal: Clin Infect Dis Date: 2011-08-31 Impact factor: 9.079
Authors: Jeffrey S Gerber; Adam L Hersh; Matthew P Kronman; Jason G Newland; Rachael K Ross; Talene A Metjian Journal: Infect Control Hosp Epidemiol Date: 2017-05-31 Impact factor: 3.254
Authors: George A Syrogiannopoulos; Aspasia N Michoula; Georgios Tsimitselis; Katerina Vassiou; Denise C Chryssanthopoulou; Ioanna N Grivea Journal: Infect Dis (Lond) Date: 2016-06-20
Authors: Tim Lynch; Liza Bialy; James D Kellner; Martin H Osmond; Terry P Klassen; Tamara Durec; Robin Leicht; David W Johnson Journal: PLoS One Date: 2010-08-06 Impact factor: 3.240
Authors: Brian Wahl; Katherine L O'Brien; Adena Greenbaum; Anwesha Majumder; Li Liu; Yue Chu; Ivana Lukšić; Harish Nair; David A McAllister; Harry Campbell; Igor Rudan; Robert Black; Maria Deloria Knoll Journal: Lancet Glob Health Date: 2018-07 Impact factor: 26.763
Authors: Justin Z Chen; Holly L Hoang; Maryna Yaskina; Dima Kabbani; Karen E Doucette; Stephanie W Smith; Cecilia Lau; Jackson Stewart; Karen Zurek; Morgan Schultz; Carlos Cervera Journal: PLoS One Date: 2022-03-23 Impact factor: 3.240